Erratum: The International/Canadian Hereditary Angioedema Guideline (Allergy Asthma Clin Immunol (2020) 16 (33) DOI: 10.1186/s13223-019-0376-8)

Stephen Betschel; Jacquie Badiou; Karen Binkley; Rozita Borici-Mazi; Jacques Hébert; Amin Kanani; Paul Keith; Gina Lacuesta; Susan Waserman; Bill Yang; Emel Aygören-Pürsün; Jonathan Bernstein; Konrad Bork; Teresa Caballero; Marco Cicardi; Timothy Craig; Henriette Farkas; Anete Grumach; Connie Katelaris; Hilary Longhurst; Marc Riedl; Bruce Zuraw; Magdelena Berger; Jean Nicolas Boursiquot; Henrik Boysen; Anthony Castaldo; Hugo Chapdelaine; Lori Connors; Lisa Fu; Dawn Goodyear; Alison Haynes; Palinder Kamra; Harold Kim; Kelly Lang-Robertson; Eric Leith; Christine McCusker; Bill Moote; Andrew O'Keefe; Ibraheem Othman; Man Chiu Poon; Bruce Ritchie; Charles St-Pierre; Donald Stark; Ellie Tsai

doi:10.1186/s13223-020-00430-4

Erratum: The International/Canadian Hereditary Angioedema Guideline (Allergy Asthma Clin Immunol (2020) 16 (33) DOI: 10.1186/s13223-019-0376-8)

Stephen Betschel, Jacquie Badiou, Karen Binkley, Rozita Borici-Mazi, Jacques Hébert, Amin Kanani, Paul Keith, Gina Lacuesta, Susan Waserman, Bill Yang, Emel Aygören-Pürsün, Jonathan Bernstein, Konrad Bork, Teresa Caballero, Marco Cicardi, Timothy Craig, Henriette Farkas, Anete Grumach, Connie Katelaris, Hilary LonghurstMarc Riedl, Bruce Zuraw, Magdelena Berger, Jean Nicolas Boursiquot, Henrik Boysen, Anthony Castaldo, Hugo Chapdelaine, Lori Connors, Lisa Fu, Dawn Goodyear, Alison Haynes, Palinder Kamra, Harold Kim, Kelly Lang-Robertson, Eric Leith, Christine McCusker, Bill Moote, Andrew O'Keefe, Ibraheem Othman, Man Chiu Poon, Bruce Ritchie, Charles St-Pierre, Donald Stark, Ellie Tsai

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Following the publication of this article [1], the authors requested to amend the characterisation of lanadelumab from humanised to the correct fully human. Therefore, the fourth paragraph under Recommendation #24 should be amended to read: Lanadelumab (Takeda), a fully human monoclonal antibody against kallikrein, takes approximately 70 days to reach a steady state concentration [110], and is therefore not recommended for STP Similarly, the first paragraph under Recommendation #27 should be amended to read: Lanadelumab is a subcutaneously injectable, fully human, anti-active plasma kallikrein monoclonal antibody (IgG1/K-light chain).

Original language	English (US)
Article number	16
Journal	Allergy, Asthma and Clinical Immunology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1186/s13223-020-00430-4
State	Published - May 6 2020

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology
Pulmonary and Respiratory Medicine

Access to Document

10.1186/s13223-020-00430-4

Cite this

Betschel, S., Badiou, J., Binkley, K., Borici-Mazi, R., Hébert, J., Kanani, A., Keith, P., Lacuesta, G., Waserman, S., Yang, B., Aygören-Pürsün, E., Bernstein, J., Bork, K., Caballero, T., Cicardi, M., Craig, T., Farkas, H., Grumach, A., Katelaris, C., ... Tsai, E. (2020). Erratum: The International/Canadian Hereditary Angioedema Guideline (Allergy Asthma Clin Immunol (2020) 16 (33) DOI: 10.1186/s13223-019-0376-8). Allergy, Asthma and Clinical Immunology, 16(1), Article 16. https://doi.org/10.1186/s13223-020-00430-4

@article{12f6cb141e254a48b31f98910886e399,

title = "Erratum: The International/Canadian Hereditary Angioedema Guideline (Allergy Asthma Clin Immunol (2020) 16 (33) DOI: 10.1186/s13223-019-0376-8)",

abstract = "Following the publication of this article [1], the authors requested to amend the characterisation of lanadelumab from humanised to the correct fully human. Therefore, the fourth paragraph under Recommendation \#24 should be amended to read: Lanadelumab (Takeda), a fully human monoclonal antibody against kallikrein, takes approximately 70 days to reach a steady state concentration [110], and is therefore not recommended for STP Similarly, the first paragraph under Recommendation \#27 should be amended to read: Lanadelumab is a subcutaneously injectable, fully human, anti-active plasma kallikrein monoclonal antibody (IgG1/K-light chain).",

author = "Stephen Betschel and Jacquie Badiou and Karen Binkley and Rozita Borici-Mazi and Jacques H{\'e}bert and Amin Kanani and Paul Keith and Gina Lacuesta and Susan Waserman and Bill Yang and Emel Ayg{\"o}ren-P{\"u}rs{\"u}n and Jonathan Bernstein and Konrad Bork and Teresa Caballero and Marco Cicardi and Timothy Craig and Henriette Farkas and Anete Grumach and Connie Katelaris and Hilary Longhurst and Marc Riedl and Bruce Zuraw and Magdelena Berger and Boursiquot, \{Jean Nicolas\} and Henrik Boysen and Anthony Castaldo and Hugo Chapdelaine and Lori Connors and Lisa Fu and Dawn Goodyear and Alison Haynes and Palinder Kamra and Harold Kim and Kelly Lang-Robertson and Eric Leith and Christine McCusker and Bill Moote and Andrew O'Keefe and Ibraheem Othman and Poon, \{Man Chiu\} and Bruce Ritchie and Charles St-Pierre and Donald Stark and Ellie Tsai",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s). Reference:.",

year = "2020",

month = may,

day = "6",

doi = "10.1186/s13223-020-00430-4",

language = "English (US)",

volume = "16",

journal = "Allergy, Asthma and Clinical Immunology",

issn = "1710-1484",

publisher = "BioMed Central",

number = "1",

}

Betschel, S, Badiou, J, Binkley, K, Borici-Mazi, R, Hébert, J, Kanani, A, Keith, P, Lacuesta, G, Waserman, S, Yang, B, Aygören-Pürsün, E, Bernstein, J, Bork, K, Caballero, T, Cicardi, M, Craig, T, Farkas, H, Grumach, A, Katelaris, C, Longhurst, H, Riedl, M, Zuraw, B, Berger, M, Boursiquot, JN, Boysen, H, Castaldo, A, Chapdelaine, H, Connors, L, Fu, L, Goodyear, D, Haynes, A, Kamra, P, Kim, H, Lang-Robertson, K, Leith, E, McCusker, C, Moote, B, O'Keefe, A, Othman, I, Poon, MC, Ritchie, B, St-Pierre, C, Stark, D & Tsai, E 2020, 'Erratum: The International/Canadian Hereditary Angioedema Guideline (Allergy Asthma Clin Immunol (2020) 16 (33) DOI: 10.1186/s13223-019-0376-8)', Allergy, Asthma and Clinical Immunology, vol. 16, no. 1, 16. https://doi.org/10.1186/s13223-020-00430-4

TY - JOUR

T1 - Erratum

T2 - The International/Canadian Hereditary Angioedema Guideline (Allergy Asthma Clin Immunol (2020) 16 (33) DOI: 10.1186/s13223-019-0376-8)

AU - Betschel, Stephen

AU - Badiou, Jacquie

AU - Binkley, Karen

AU - Borici-Mazi, Rozita

AU - Hébert, Jacques

AU - Kanani, Amin

AU - Keith, Paul

AU - Lacuesta, Gina

AU - Waserman, Susan

AU - Yang, Bill

AU - Aygören-Pürsün, Emel

AU - Bernstein, Jonathan

AU - Bork, Konrad

AU - Caballero, Teresa

AU - Cicardi, Marco

AU - Craig, Timothy

AU - Farkas, Henriette

AU - Grumach, Anete

AU - Katelaris, Connie

AU - Longhurst, Hilary

AU - Riedl, Marc

AU - Zuraw, Bruce

AU - Berger, Magdelena

AU - Boursiquot, Jean Nicolas

AU - Boysen, Henrik

AU - Castaldo, Anthony

AU - Chapdelaine, Hugo

AU - Connors, Lori

AU - Fu, Lisa

AU - Goodyear, Dawn

AU - Haynes, Alison

AU - Kamra, Palinder

AU - Kim, Harold

AU - Lang-Robertson, Kelly

AU - Leith, Eric

AU - McCusker, Christine

AU - Moote, Bill

AU - O'Keefe, Andrew

AU - Othman, Ibraheem

AU - Poon, Man Chiu

AU - Ritchie, Bruce

AU - St-Pierre, Charles

AU - Stark, Donald

AU - Tsai, Ellie

PY - 2020/5/6

Y1 - 2020/5/6

N2 - Following the publication of this article [1], the authors requested to amend the characterisation of lanadelumab from humanised to the correct fully human. Therefore, the fourth paragraph under Recommendation #24 should be amended to read: Lanadelumab (Takeda), a fully human monoclonal antibody against kallikrein, takes approximately 70 days to reach a steady state concentration [110], and is therefore not recommended for STP Similarly, the first paragraph under Recommendation #27 should be amended to read: Lanadelumab is a subcutaneously injectable, fully human, anti-active plasma kallikrein monoclonal antibody (IgG1/K-light chain).

AB - Following the publication of this article [1], the authors requested to amend the characterisation of lanadelumab from humanised to the correct fully human. Therefore, the fourth paragraph under Recommendation #24 should be amended to read: Lanadelumab (Takeda), a fully human monoclonal antibody against kallikrein, takes approximately 70 days to reach a steady state concentration [110], and is therefore not recommended for STP Similarly, the first paragraph under Recommendation #27 should be amended to read: Lanadelumab is a subcutaneously injectable, fully human, anti-active plasma kallikrein monoclonal antibody (IgG1/K-light chain).

UR - https://www.scopus.com/pages/publications/85084935166

UR - https://www.scopus.com/inward/citedby.url?scp=85084935166&partnerID=8YFLogxK

U2 - 10.1186/s13223-020-00430-4

DO - 10.1186/s13223-020-00430-4

M3 - Comment/debate

C2 - 32399057

AN - SCOPUS:85084935166

SN - 1710-1484

VL - 16

JO - Allergy, Asthma and Clinical Immunology

JF - Allergy, Asthma and Clinical Immunology

IS - 1

M1 - 16

ER -

Erratum: The International/Canadian Hereditary Angioedema Guideline (Allergy Asthma Clin Immunol (2020) 16 (33) DOI: 10.1186/s13223-019-0376-8)

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this